Roche: We’ve Abandoned Budgets And It’s Liberated Employees
Executive Summary
Bill Anderson says Roche has scrapped budgets and improved productivity and re-energised teams. But is it too good to be true?
You may also be interested in...
Pharma Leader Bill Anderson Makes Rapid Exit From Roche
Bill Anderson is leaving Roche after leading its pharma division through the loss of three oncology blockbusters and the launch of a new generation of blood cancer therapies.
Bucking Biosimilar Threat, Roche Sees Further Growth
Many new and pipeline products were highlighted at London meeting – but no word on Spark Therapeutics deal. New products will have high profit margins.
GSK Revamps Sales Reps Incentives To Be Competitive In Cancer
Seven years after a major shift in how the company compensated its sales force, the UK major has done a U-turn and is adapting pay packages for some specialty care reps.